NEW YORK (GenomeWeb) – DiaGenomi and biotech consulting firm Healthcare Economics have formed a joint venture to bring DiaGenomi's pathology-assisted MyRisq genetic tests to the North American market, the companies said today.

DiaGenomi, which has offices in the UK and in Slovenia, offers a number of tests that combine DNA analysis with information about lifestyle, medical history, and blood tests to provide a report with a personalized risk assessment for conditions such as cardiovascular disease, sports injury, or multiple sclerosis.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.